Adamas Pharmaceuticals Inc. is a leading specialty pharmaceutical company that is primarily focused on developing and commercializing therapeutics that aim to address chronic disorders related to the central nervous system. Its top product candidate, ADS-5102, has recently completed a successful phase II/III clinical trial for the treatment of Parkinson's disease. This disease often leads to levodopa induced dyskinesia, and ADS-5102 could be a potential solution for this problem. The company is primarily based in the United States and has made significant progress in the field of neurology, with several other innovative products in its pipeline.
Adamas Pharmaceuticals Inc's ticker is ADMS
The company's shares trade on the NASDAQ stock exchange
They are based in Emeryville, California
There are 51-200 employees working at Adamas Pharmaceuticals Inc
It is http://www.adamaspharma.com/
Adamas Pharmaceuticals Inc is in the Healthcare sector
Adamas Pharmaceuticals Inc is in the Drugs - Generic industry
The following five companies are Adamas Pharmaceuticals Inc's industry peers: